Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

210.33
+1.030.49%
Post-market: 210.390.0600+0.03%17:50 EST
Volume:8.46M
Turnover:1.78B
Market Cap:506.75B
PE:20.33
High:211.52
Open:209.39
Low:208.46
Close:209.30
52wk High:215.19
52wk Low:140.68
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.92
T/O Rate:0.35%
Dividend:5.08
Dividend Rate:2.42%
EPS(TTM):10.35
EPS(LYR):5.84
ROE:33.62%
ROA:8.26%
PB:6.39
PE(LYR):36.00

Loading ...

Ema's Chmp: Recommended Extensions of Indication for Arexvy, Aspaveli, Dovprela, Elucirem, Eylea, Nucala, Recarbrio, Simponi, Uplizna, Vueway

THOMSON REUTERS
·
Dec 12

Johnson & Johnson Positioned for Growth on Multiple MedTech and Immunology Catalysts, RBC Says

MT Newswires Live
·
Dec 12

Johnson & Johnson Is Maintained at Outperform by RBC Capital

Dow Jones
·
Dec 11

Adagio Medical Holdings Appoints Sean Salmon to Board of Directors

Reuters
·
Dec 11

Citigroup Adjusts Price Target on Johnson & Johnson to $232 From $215, Maintains Buy Rating

MT Newswires Live
·
Dec 11

Microsoft, Broadcom, Lilly, and Other Stocks That Meet This Pro's Definition of 'Quality' -- Barrons.com

Dow Jones
·
Dec 11

J&J : RBC Raises Target Price to $230 From $209

THOMSON REUTERS
·
Dec 11

Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says

MT Newswires Live
·
Dec 11

Dow Up 189 Points On Gains For Shares Of Nike, American Express

Dow Jones
·
Dec 11

Johnson & Johnson : HSBC Raises Target Price to $240 From $215

THOMSON REUTERS
·
Dec 10

Cancer Study Buoys These Small Biotechs -- Barrons.com

Dow Jones
·
Dec 10

FDA Probes IF Covid Shots Might Be Linked to Deaths of Adults- Bloomberg News

THOMSON REUTERS
·
Dec 10

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Benzinga
·
Dec 10

Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma

MT Newswires Live
·
Dec 09

BRIEF-Unprecedented Results From The Phase 3 MajesTEC-3 Study Support TECVAYLI Plus DARZALEX FASPRO As A Potential Standard Of Care As Early As Second Line For Patients With Relapsed/Refractory Multiple Myeloma

Reuters
·
Dec 09

FDA Reviews Johnson & Johnson's TECVAYLI and DARZALEX FASPRO Combination for Multiple Myeloma

Reuters
·
Dec 09

J&J - Tecvayli and Darzalex Show Significant Survival Advantage

THOMSON REUTERS
·
Dec 09

J&J - Submits Sbla for Tecvayli and Darzalex Combination as Treatment for Rrmm

THOMSON REUTERS
·
Dec 09

Unprecedented Results From the Phase 3 Majestec-3 Study Support Tecvayli® Plus Darzalex Faspro® as a Potential Standard of Care as Early as Second Line for Patients With Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Dec 09

Perrigo Co. PLC Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Dec 09